HCQ Dose (mg/kg/day) | Pre-intervention | Post-intervention | ||
---|---|---|---|---|
Rheumatology, n (%) n = 1128 | Dermatology, n (%) n = 282 | Rheumatology, n (%) n = 1161 | Dermatology, n (%) n = 110 | |
≤ 5.0 | 778 (68.9) | 170 (60.3) | 894 (77.0) | 82 (74.5) |
Female | 626 (80.555.5) | 122 (71.843.3) | 708 (79.261.0) | 56 (68.350.9) |
Lupusa | 148 (23.613.1) | 12 (9.8 (4.3) | 79 (11.26.8) | 9 (16.18.2) |
RA | 201 (32.117.8) | 0 | 133 (18.811.5) | 0 |
Male | 152 (19.513.5) | 48 (28.217.0) | 186 (20.816.0) | 26 (31.723.6) |
Lupusa | 16 (10.51.4) | 10 (20.83.5) | 11 (5.90.9) | 6 (23.15.5) |
RA | 64 (42.15.7) | 0 | 55 (29.64.7) | 0 |
5.1–6.5 | 277 (24.6) | 78 (27.7) | 222 (19.1) | 22 (20.0) |
Female | 256 (92.422.7) | 65 (83.323.0) | 197 (88.717.0) | 19 (86.417.3) |
Lupusa | 70 (27.36.2) | 10 (15.43.5) | 20 (10.21.7) | 3 (15.82.7) |
RA | 61 (23.85.4) | 0 | 38 (19.33.3) | 0 |
Male | 21 ((1.9)7.6) | 13 (16.74.6) | 25 (11.32.2) | 3 (13.62.7) |
Lupusa | 4 (19.00.35) | 3 (23.11.1) | 2 (0.10.2) | 1 (33.30.9) |
RA | 11 (52.40.98) | 0 | 10 (0.40.9) | 0 |
≥ 6.6 | 73 (6.5) | 34 (12.1) | 45 (3.9) | 6 (5.5) |
Female | 70 (95.96.2) | 32 (94.111.3) | 42 (93.33.6) | 4 (66.73.6) |
Lupusa | 17 (24.31.5) | 3 (9.41.1) | 2 (4.80.2) | 0 |
RA | 17 (24.31.5) | 0 | 5 (11.90.4) | 0 |
Male | 3 (4.10.27) | 2 (5.90.71) | 3 (6.70.3) | 2 (33.31.8) |
Lupusa | 0 | 0 | 0 | 0 |
RA | 2 (66.70.18) | 0 | 2 (66.70.2) | 0 |